Cartesian Therapeutics
(NASDAQ) RNAC
Cartesian Therapeutics Financials at a Glance
Market Cap
$178.94M
Revenue (TTM)
$2.80M
Net Income (TTM)
$130.30M
EPS (TTM)
$-5.02
P/E Ratio
-1.34
Dividend
$0.00
Beta (Volatility)
1.59 (High)
Dividend
$0.00
Beta (Volatility)
1.59 (High)
Price
$7.04
Volume
5,253
Open
$6.90
Price
$7.04
Volume
5,253
Open
$6.90
Previous Close
$6.75
Daily Range
$6.90 - $7.28
52-Week Range
$5.60 - $15.57
Dividend
$0.00
Beta (Volatility)
1.59 (High)
Price
$7.04
Volume
5,253
Open
$6.90
Previous Close
$6.75
Daily Range
$6.90 - $7.28
52-Week Range
$5.60 - $15.57
RNAC News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cartesian Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
75
CEO
Carsten Brunn, PhD
Headquarters
Watertown, MA 02472, US
RNAC Financials
Key Financial Metrics (TTM)
Gross Margin
-4%
Operating Margin
-31%
Net Income Margin
-47%
Return on Equity
0%
Return on Capital
-31%
Return on Assets
-44%
Earnings Yield
-74.63%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$178.94M
Shares Outstanding
26.51M
Volume
5.25K
Short Interest
0.00%
Avg. Volume
190.03K
Financials (TTM)
Gross Profit
$2.80M
Operating Income
$86.70M
EBITDA
$86.70M
Operating Cash Flow
$73.94M
Capital Expenditure
$5.45M
Free Cash Flow
$79.39M
Cash & ST Invst.
$125.14M
Total Debt
$12.68M
Cartesian Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$947.00K
+224.8%
Gross Profit
$947.00K
+224.8%
Gross Margin
100.00%
N/A
Market Cap
$178.94M
N/A
Market Cap/Employee
$2.71M
N/A
Employees
66
N/A
Net Income
$92.58M
-802.9%
EBITDA
$21.94M
-131.4%
Quarterly Fundamentals
Net Cash
$112.46M
-43.4%
Accounts Receivable
$1.11M
+27.9%
Inventory
$0.00
N/A
Long Term Debt
$8.53M
-23.4%
Short Term Debt
$4.15M
+45.6%
Return on Assets
-43.96%
N/A
Return on Invested Capital
-30.80%
N/A
Free Cash Flow
$18.20M
-136.2%
Operating Cash Flow
$17.71M
-153.0%